Abstract
When an Ebola outbreak began ravaging West Africa in 2013, doctors and scientists had few medicines to treat the thousands of people who would become infected with the deadly virus in the years to follow. In fact, no antiviral therapeutics have received regulatory approval or demonstrated clinical efficacy against Ebola to date. There might be new hope, though, thanks to researchers at Gilead Sciences, the U.S. Army Medical Research Institute of Infectious Diseases, the Centers for Disease Control & Prevention, and Boston University. Those scientists, who presented in San Diego, have developed a small molecule called GS-5734 that’s effective at treating monkeys infected with the Ebola virus (Nature 2016, DOI: 10.1038/nature17180). GS-5734 is a monophosphoramidate prodrug of an adenosine analog. Once the small molecule is administered, enzymes in the body cleave GS-5734’s monophosphoramidate and eventually replace it with a triphosphate. This metabolite, the researchers suspect, inhibits the virus’s RNA-dependent RNA
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
